Briumvi momentum remains strong, while subcutaneous catalysts and elevated manufacturing investment shape 2026 execution.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-02-27 |
| Length | 37 minutes |
| EPS | $0.14 |
| EPS consensus | $0.35 |
| Revenue | $192.6M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q2 FY25
Read the full Q4 FY25 earnings call transcript
All TGTX earnings · Back to TGTX overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.